慢性肾脏病-矿物质和骨异常:发病机制与管理。
Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management.
机构信息
Bone and Mineral Research Unit, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Retic REDinREN-ISCIII, Avda. Roma, sn., 33011, Oviedo, Spain.
Department of Medicine, Universidad de Oviedo, Oviedo, Spain.
出版信息
Calcif Tissue Int. 2021 Apr;108(4):410-422. doi: 10.1007/s00223-020-00777-1. Epub 2020 Nov 15.
The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive reduction of kidney function greatly modifies the tightly interrelated mechanisms that control these parameters. As a result, important changes occur in the bone and mineral hormonal axis, leading to changes in bone turnover with relevant consequences in clinical outcomes, such as decrease in bone mass with increased bone fragility and bone fractures and increased vascular and valvular calcification, also with great impact in the cardiovascular outcomes. So far, the knowledge of the mineral and bone disorders in CKD and the increased variety of efficacious therapies should lead to a better prevention and management of CKD-MBD.
慢性肾脏病-矿物质和骨异常(CKD-MBD)的关键因素包括钙、磷、甲状旁腺激素(PTH)、成纤维细胞生长因子 23(FGF23)和维生素 D 激素系统。肾功能的逐渐下降极大地改变了控制这些参数的紧密相关的机制。结果,骨和矿物质激素轴发生重要变化,导致骨转换发生变化,从而对临床结局产生相关影响,如骨量减少、骨脆性增加、骨折增加以及血管和瓣膜钙化增加,这对心血管结局也有重大影响。到目前为止,对 CKD 中矿物质和骨异常的认识以及更有效的治疗方法的多样性,应该能够更好地预防和管理 CKD-MBD。